the aid library

LIST OPTIONS

Filter

12078

Sort by:

Direction:

Download (108)

View PDF (89)

Results Report - Programme budget 2020–2021 - Executive Summary

World Health Organization (WHO) World Health Organization (WHO) (2022) CC

This results report for the biennium 2020–2021 presents the progress towards the triple billion targets, outcomes and outputs, based on the GPW 13 results framework and indicators. It uses structured methodologies, both quantitative and qualitative, for measuring and analysing the achievements and... more

Download (149)

View PDF (193)

WHO global air quality guidelines: particulate matter (‎PM2.5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

World Health Organization WHO (2021) C_WHO

The global burden of disease associated with air pollution exposure exacts a massive toll on human health worldwide: exposure to air pollution is estimated to cause millions of deaths and lost years of healthy life annually. The burden of disease attributable to air pollution is now estimated to be ... more

Download (247)

View PDF (332)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (179)

View PDF (220)

Panorama de la diabetes en la Región de las Américas

Pan American Health Organization (PAHO) (2022) C_WHO

La carga de la diabetes es enorme, posicionándola como uno de los principales desafíos que enfrenta la salud pública en la actualidad. Actualmente, se estima que 62 millones de personas viven con diabetes en la Región de las Américas y las proyecciones muestran que su prevalencia seguirá aumen... more

Download (160)

View PDF (162)

Regional action framework for noncommunicable disease prevention and control in the Western Pacific

World Health Organisation (WHO) (2023) C_WHO

The Regional Action Framework for Noncommunicable Disease Prevention and Control provides a unified vision of objectives and recommended actions to combat the noncommunicable disease (‎NCD)‎ epidemic in the Western Pacific Region. Implementation should be supported by cross-sectoral coordination... more

Download (92)

View PDF (115)

A glimpse into WHO work in Botswana

World Health Organisation (WHO) (2023) C_WHO

This publication articulates the WHO Botswana Country Office’s focus and investment needs for the biennium 2022–2023, building on achievements, networks, and partnerships fostered in 2020-2021. As the leading health authority within the United Nations system in Botswana, the WHO Country Offi... more

Download (181)

View PDF (152)

Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030

World Health Organization WHO (2023) C_WHO

The Pandemic Influenza Pandemic (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the strategy for strengthening global pandemic influenza preparedness from 2024 to 2030. HLIP III takes into consideration the lessons learned from the response to t... more

Download (233)

View PDF (191)

Self-care interventions: human papillomavirus (‎HPV)‎ self-sampling as part of cervical cancer screening and treatment, 2022 update

World Health Organisation (WHO) (2023) C_WHO

Self-care interventions are evidence-based, quality drugs, devices, diagnostics and/or digital products which can be provided fully or partially outside of formal health services and can be used with or without the direct supervision of health care personnel. Where HPV tests are available as part o... more

Download (75)

View PDF (254)

The Expanded Special Project for Elimination of Neglected Tropical diseases — ESPEN

World Health Organization WHO (2023) C_WHO

Accessed on 10.04.2023 While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chroni... more

Download (87)

View PDF (550)

Exploring the cultural effects of gender on perceptions of cutaneous leishmaniasis: a systematic literature review

Wenning, B., Price, H., Nuwangi, H. et al. Global Health Research and Policy (2022) CC

More than one million people each year become infected by parasites that cause the disease cutaneous leishmaniasis (CL). This disease manifests as one or more skin lesions or ulcers that are slow to heal with variable response rates to drug treatments. Thus far, little attention has been paid to how... more

Download (168)

View PDF (205)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (88)

View PDF (223)

Global snakebite burden Report by the Director-General

World Health Organization WHO (2018) C_WHO

Snakebite envenoming is a potentially life-threatening disease that typically results from the injection of a mixture of different toxins (“venom”) following the bite of a venomous snake. Envenoming can also be caused by venom being sprayed into a person’s eyes by certain species of snakes tha... more

Download (95)

View PDF (490)

The social context of schistosomiasis and its control: an introduction and annotated bibliography

Bruun, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO; Institutional Repository for Information Sharing iris (2008) C_WHO

Schistosomiasis is widely recognized as a disease that is socially determined. An understanding of the social and behavioural factors linked to disease transmission and control should play a vital role in designing policies and strategies for schistosomiasis prevention and control. To this must b... more

Download (102)

View PDF (317)

United against Rabies Collaboration

World Health Organization WHO (2019) C_WHO

Rabies is entirely preventable, and vaccines, medicines, tools and technologies have long been available to prevent people from dying of dog-mediated rabies. Nevertheless, rabies still kills about 60 000 people a year, of whom over 40% are children under 15, mainly in rural areas of economically dis... more

Download (144)

View PDF (178)

Human and dog rabies prevention and control

World Health Organization WHO; Bill & Melinda Gates Foundation (2009) C_WHO

Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,... more

Download (126)

View PDF (170)

WHO interim guidelines for the treatment of gambiense human African trypanosomiasis

World Health Organization WHO (2019) C_WHO

This document focuses on the management of patients affected by gambiense HAT and constitutes an update to the WHO therapeutic guidance issued in 2013. The main changes in recommendations concern the criteria and methods for deciding the treatment among the new set of therapeutic options and the pa... more

Download (241)

View PDF (193)

Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer: executive summary

World Health Organization WHO (2023) C_WHO

Breast cancer is the most common cancer worldwide and the leading cause of cancer deaths among women, disproportionately affecting low- and middle-income countries. The Global Breast Cancer Initiative strives to reduce breast cancer mortality by 2.5 percent per year, which over a 20-year period can ... more

Download (101)

View PDF (304)

The social context of schistosomiasis and its control

Brunn, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO (2008) C_WHO

Download (2057)

View PDF (2409)

WHO Monographs On Selected Medicinal Plants - Volume 3

World Health Organization WHO (2007) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

Download (154)

View PDF (192)

Mpox Strategic Preparedness, Readiness, and Response Plan: Global Monitoring and Evaluation Framework

World Health Organization WHO Reliefweb OCHA Services (2022) C_WHO

This Mpox SPRP Global Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress towards these objectives, including information about country-level response efforts and WHO support to Member States. Regular collection and analysis of da... more